Effects of hyperthermia on the peripheral nervous system: a review

被引:42
作者
Haveman, J
Van der Zee, J
Wondergem, J
Hoogeveen, JF
Hulshof, MCCM
机构
[1] Acad Med Ctr, Dept Radiotherapy, NL-1100 DE Amsterdam, Netherlands
[2] Erasmus MC Daniel den Hoed Canc Ctr, Dept Radiat Oncol, Hyperthermia Unit, Rotterdam, Netherlands
[3] Leids Univ Med Ctr, Dept Clin Oncol, Leiden, Netherlands
关键词
hyperthermia; hyperthermic oncology; whole-body hyperthermia; isolated limb perfusion; multiple sclerosis; peripheral nerve;
D O I
10.1080/02656730310001637631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present paper overviews the current knowledge about effects of hyperthermia at temperatures used in clinical oncology on the peripheral nervous system. From the experimental studies it may be concluded that the heat sensitivity of the nerve is determined by the sensitivity of the nerve vasculature. These studies show that in order to avoid induction of severe neuropathy, application of heat to the peripheral nerves should not be in excess of doses of 30 min at 44degreesC or equivalent. Using modern equipment for application of loco-regional hyperthermia the incidence of even mild neurological complications is very low. In hyperthermic isolated limb perfusion (HILP) tneurotoxicity is an often-mentioned side effect, this is in spite of the fact that in all studies a relatively mild hyperthermic temperature is used that, based on the experimental studies, should be well tolerated by the nerves and other normal tissues in the limbs. It seems that the neurotoxicity observed after HILP results from thermal enhancement of drug toxicity, very probably combined with effects of a high tourniquet pressure that is used to isolate the blood flow in the leg. Whole body hyperthermia (WBH), using anesthesia and appropriate monitoring to avoid cardiovascular stress is at present considered a safe procedure. Still in the recent past cases of neuropathy after treatment have been described. When chemotherapy, and notably cisplatin, is administered before or during hyperthermia there are several clinical and experimental observations that indicate a limited tolerance of the peripheral nervous tissue in such case. Also previous radiotherapy may limit the tolerance of nerves to hyperthermia, notably when radiation is applied with a large field size. Experimental studies show that combined treatment with radiation and heat leads to enhancement of effects of radiation (enhancement ratio similar to1.5 at 60 min at 44degreesC). A clear contraindication for the application of hyperthermia in patients is the presence of a neurodegenerative disease, such as multiple sclerosis. Vigilance is also required in the treatment of diabetic patients with hyperthermia, this based on experimental animal studies, but so far no clear clinical data are available.
引用
收藏
页码:371 / 391
页数:21
相关论文
共 82 条
[1]  
ADAM AM, 1987, LANCET, V1, P1270
[2]  
ADAM AM, 1982, LANCET, V61, P377
[3]  
BARLOGIE B, 1979, CANCER RES, V39, P1481
[4]   PERIPHERAL NEUROPATHY AND MYONECROSIS FOLLOWING HYPERTHERMIA AND RADIATION-THERAPY FOR RECURRENT PROSTATIC-CANCER - CORRELATION OF DAMAGE WITH PREDICTED SAR PATTERN [J].
BENYOSEF, R ;
SULLIVAN, DM ;
KAPP, DS .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1992, 8 (02) :173-185
[5]   PERSISTENT NEUROLOGICAL DEFICIT PRECIPITATED BY HOT BATH TEST IN MULTIPLE-SCLEROSIS [J].
BERGER, JR ;
SHEREMATA, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 249 (13) :1751-1753
[6]   Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents [J].
Bonifati, DM ;
Ori, C ;
Rossi, CR ;
Caira, S ;
Fanin, M ;
Angelini, C .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) :517-522
[7]  
BOULANT JA, 1973, AM J PHYSIOL, V225, P1371, DOI 10.1152/ajplegacy.1973.225.6.1371
[8]   REVERSIBLE HEAT LESIONS WITH RADIOFREQUENCY CURRENT - METHOD OF STEREOTACTIC LOCALIZATION [J].
BRODKEY, JS ;
ERVIN, FR ;
MIYAZAKI, Y ;
MARK, VH .
JOURNAL OF NEUROSURGERY, 1964, 21 (01) :49-&
[9]   WHOLE-BODY HYPERTHERMIA - PHASE-I TRIAL OF A POTENTIAL ADJUVANT TO CHEMOTHERAPY [J].
BULL, JM ;
LEES, D ;
SCHUETTE, W ;
WHANGPENG, J ;
SMITH, R ;
BYNUM, G ;
ATKINSON, ER ;
GOTTDIENER, JS ;
GRALNICK, HR ;
SHAWKER, TH ;
DEVITA, VT .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (03) :317-323
[10]  
BUSSE O, 1983, RECENT RES CANCER, V86, P264